Celltrion is continuing to spearhead global competition to Genentech/Novartis’s Xolair (omalizumab), now picking up an approval from the UK’s Medicines and Healthcare products Regulatory Agency for its Omlyclo biosimilar treatment for allergic asthma and chronic rhinosinusitis with nasal polyps.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?